-
1 Comment
Beijing Beilu Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.0% below its 200 day moving average.
From a valuation standpoint, the stock is 43.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Beijing Beilu Pharmaceutical Co., Ltd's total revenue sank by 3.6% to $204M since the same quarter in the previous year.
Its net income has dropped by 91.9% to $14M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.0% to $1M since the same quarter in the previous year.
Based on the above factors, Beijing Beilu Pharmaceutical Co., Ltd gets an overall score of 1/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CNE000001QK9 |
| Exchange | SHE |
| CurrencyCode | CNY |
| Market Cap | 3B |
|---|---|
| PE Ratio | 205.0 |
| Beta | 0.37 |
| Target Price | None |
| Dividend Yield | None |
Beijing Beilu Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd. also produces precision medicine. The company was founded in 1992 and is based in Beijing, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300016.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
